Shuwen Biotech

About Shuwen Biotech

Shuwen Biotech, established in 2010, is a diagnostic company with a global presence, maintaining offices in both China and Germany. The company was founded by Dr. Jay Z. Zhang, who now serves as Chairman and CEO. His extensive background spans over three decades in the biotech industry, including roles as a research scientist at Merck & Co., Inc., a senior vice president at Myriad Genetics, and co-founder of Niiki Pharma Inc. This deep experience in research, patent law, and corporate management has shaped Shuwen's strategic direction, which is centered on in-house innovation, robust patent protection, and international collaboration.

The company focuses on developing and commercializing novel in-vitro diagnostic (IVD) products, with a primary emphasis on women's health, particularly in oncology and maternal-fetal medicine. Its business model involves a multi-faceted approach. Shuwen develops proprietary diagnostic assays, provides central lab biomarker testing services for hospitals and pharmaceutical developers, and manufactures certified IVD reagents. This integrated structure allows the company to serve a diverse client base, from clinicians seeking to personalize treatment to pharmaceutical companies needing companion diagnostics for their drug development pipelines. Revenue is generated through the sale of its diagnostic kits and fees from its lab services. The company's international market presence is managed through its German subsidiary, Cerca Biotech GmbH.

Shuwen’s product portfolio addresses critical needs in healthcare. A notable product is the CapCord® Preeclampsia detection kit, a first-in-class diagnostic developed in partnership with Yale University. This product, which uses a patented biomarker from the mother's urine for non-invasive testing, has received regulatory approval in China and is being promoted globally. In oncology, Shuwen offers a suite of tests for breast cancer, including maxBRCA and MammaType®, which assist in risk assessment, molecular subtyping, prognosis, and treatment guidance. The company has secured significant venture capital, completing Series B and C1 financing rounds to fund continued product development and market expansion.